Related Experiment Video
Updated: Aug 11, 2026

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression
Published on: May 15, 2014
Growth inhibitory effect of gene-cloned interferons on human myeloblast colonies
Abstract:
The effect on marrow myeloblast colony formation in blood from nine patients with acute myeloid leukemia was studied by using three recombinant-DNA-derived human leukocyte interferons (IFN alpha 2, IFN alpha-A, and IFN alpha-C). In preliminary experiments, a brief exposure of leukemic marrow cells to IFN alpha resulted in a sharp increase in the IFN-induced enzyme 2-5A synthetase, indicating the expression of IFN cell receptors as well as the ability of leukemia cells to respond metabolically. Dose-response studies showed a dose-dependent suppression of myeloblast colony formation in all experiments using concentrations of 10(2)-10(5) U/ml of the three IFN subtypes. In self-renewal assays derived from the primary cultures that initially contained IFN alpha 2, a "carryover" antiproliferative effect was observed with a dose-dependent decline in secondary growth. In comparison studies of IFN alpha-A and IFN alpha-C, the suppressive effect on primary myeloblast growth was much more pronounced with IFN alpha-C at concentrations of 10(3) U/ml and higher; in self-renewal assays, the antiproliferative effect of IFN alpha-C on secondary growth was no longer observed, whereas that of IFN alpha-A persisted. These three subtypes of gene-cloned IFN have antileukemic properties in vitro, with differences in degree of suppression of primary myeloblast growth and of self-renewal.
Insights
Three types of human leukocyte interferons (IFN) show anti-leukemic properties by suppressing myeloblast colony formation in acute myeloid leukemia patients. Interferon-alpha-C demonstrated a more pronounced effect on primary growth, while Interferon-alpha-A maintained antiproliferative effects on secondary growth.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Acute myeloid leukemia (AML) is a hematologic malignancy characterized by uncontrolled proliferation of myeloid blasts.
- Interferons (IFNs) are cytokines with known immunomodulatory and antiproliferative effects.
- Recombinant DNA technology has enabled the production of specific interferon subtypes for therapeutic research.
Purpose of the Study:
- To investigate the in vitro effects of three recombinant human leukocyte interferon subtypes (IFN alpha 2, IFN alpha-A, IFN alpha-C) on acute myeloid leukemia (AML) myeloblast colony formation.
- To assess the dose-dependent response and self-renewal capacity of AML cells exposed to these interferons.
- To compare the differential anti-leukemic properties of IFN alpha-A and IFN alpha-C.
Main Methods:
- Leukemic bone marrow cells from nine AML patients were cultured in the presence of varying concentrations (10^2-10^5 U/ml) of IFN alpha 2, IFN alpha-A, and IFN alpha-C.
- Myeloblast colony formation was assessed.
- Self-renewal assays were performed on primary cultures to evaluate secondary colony growth.
- Expression of the IFN-induced enzyme 2-5A synthetase was measured to confirm cellular response.
Main Results:
- All three tested interferon subtypes exhibited a dose-dependent suppression of myeloblast colony formation in vitro.
- A significant increase in 2-5A synthetase indicated that AML cells possess functional interferon receptors and metabolic responsiveness.
- Interferon-alpha-C showed a more potent suppression of primary myeloblast growth compared to IFN alpha-A at concentrations of 10^3 U/ml and higher.
- While IFN alpha-C's effect on secondary growth was transient, IFN alpha-A demonstrated a persistent antiproliferative effect on self-renewal.
Conclusions:
- Gene-cloned interferon subtypes possess significant in vitro antileukemic properties against acute myeloid leukemia.
- Differential effects were observed among IFN subtypes regarding the suppression of primary myeloblast proliferation and the inhibition of cancer cell self-renewal.
- These findings suggest potential for targeted interferon-based therapies in AML, with specific subtypes offering distinct advantages.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Inhibitors of Viral Protein Synthesis

